文献速递胸部肿瘤泌尿男性生殖肿瘤消化系统肿瘤

晚期实体瘤不符合试验标准的患者中免疫检查点抑制剂的使用及生存结局

Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers.
PubMed 文献 · JAMA Oncol · 2021-01-01

这项回顾性队列研究纳入美国280个以社区肿瘤实践为主的机构中34131例于2014年1月至2019年12月启动一线系统治疗的晚期实体瘤患者,其中9318例(27.3%)不符合试验标准。不符合试验标准与免疫检查点抑制剂单药使用增加相关,但在该人群中免疫检查点抑制剂与非免疫检查点抑制剂治疗之间未检测到生存差异。

要点

  • 不符合试验标准的患者中免疫检查点抑制剂单药使用比例从0%升至30.2%,符合试验标准者从0.1%升至19.4%。
  • 不符合试验标准与免疫检查点抑制剂单药使用增加相关(IPW校正OR 1.8,95%CI 1.7-1.9)。
  • 不符合试验标准患者中,免疫检查点抑制剂单药、联合治疗与非免疫检查点抑制剂治疗在12个月和36个月均无生存差异。

核心结论

  • 在不符合试验标准的晚期癌症患者中,免疫检查点抑制剂与非免疫检查点抑制剂治疗之间未检测到生存差异。
  • 免疫检查点抑制剂在3期试验中的阳性结果可能无法转化至这一脆弱人群。

研究设计与样本

  • 回顾性队列研究,纳入美国280个以社区肿瘤实践为主的机构。
  • 共纳入34131例于2014年1月至2019年12月启动一线系统治疗的新诊断转移性或复发性不可靶向非小细胞肺癌、尿路上皮癌、肾细胞癌或肝细胞癌患者。
  • 其中9318例(27.3%)不符合试验标准。
  • 数据统计分析时间为2019年12月1日至2021年6月1日。
  • 暴露因素为不符合试验标准(东部肿瘤协作组体能状态评分≥2或存在肾或肝功能异常)及一线系统治疗。

主要发现

  • 总体队列(n=34131)中位(IQR)年龄为70(62-77)岁,23586例(69%)为白人个体,14478例(42%)为女性。
  • 研究期间,不符合试验标准患者接受免疫检查点抑制剂单药治疗的比例从0%增至30.2%,符合试验标准患者从0.1%增至19.4%。
  • 不符合试验标准与免疫检查点抑制剂单药使用增加相关(与非免疫检查点抑制剂治疗相比的IPW校正比值比1.8,95%CI 1.7-1.9)。
  • 不符合试验标准患者中,免疫检查点抑制剂单药、免疫检查点抑制剂联合治疗与非免疫检查点抑制剂治疗在12个月总生存无差异(限制性平均生存时间分别为7.8、7.7、8.1个月),在36个月亦无差异(分别为15.0、13.9、14.4个月)。
  • 与非免疫检查点抑制剂治疗相比,免疫检查点抑制剂单药显示早期危害证据(6个月内IPW校正HR 1.2,95%CI 1.1-1.2),但6个月后生存者中显示晚期获益(校正HR 0.8,95%CI 0.7-0.8)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Immune checkpoint inhibitors (ICIs) are part of standard of care for patients with many advanced solid tumors. Patients with poor performance status or organ dysfunction are traditionally ineligible to partake in pivotal randomized clinical trials of ICIs. OBJECTIVE: To assess ICI use and survival outcomes among patients with advanced cancers who are traditionally trial ineligible based on poor performance status or organ dysfunction. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted in 280 predominantly community oncology practices in the US and included 34 131 patients (9318 [27.3%] trial ineligible) who initiated first-line systemic therapy from January 2014 through December 2019 for newly diagnosed metastatic or recurrent nontargetable non-small cell lung, urothelial cell, renal cell, or hepatocellular carcinoma. Data analysis was performed from December 1, 2019, to June 1, 2021. EXPOSURES: Trial ineligibility (Eastern Cooperative Oncology Group performance status ≥2 or the presence of kidney or liver dysfunction); first-line systemic therapy. MAIN OUTCOMES AND MEASURES: The association between trial ineligibility and ICI monotherapy uptake was assessed using inverse probability-weighted (IPW) logistic regressions. The comparative survival outcomes following ICI and non-ICI therapy among trial-ineligible patients were assessed using treatment IPW survival analyses. Because we observed nonproportional hazards, we reported 12-month and 36-month restricted mean survival times (RMSTs) and time-varying hazard ratios (HRs) of less than 6 months and 6 months or greater. RESULTS: Among the overall cohort (n = 34 131), the median (IQR) age was 70 (62-77) years; 23 586 (69%) were White individuals, and 14 478 (42%) were women. Over the study period, the proportion of patients receiving ICI monotherapy increased from 0% to 30.2% among trial-ineligible patients and 0.1% to 19.4% among trial-eligible patients. Trial ineligibility was associated with increased ICI monotherapy use (IPW-adjusted odds ratio compared with non-ICI therapy, 1.8; 95% CI, 1.7-1.9). Among trial-ineligible patients, there were no overall survival differences between ICI monotherapy, ICI combination therapy, and non-ICI therapy at 12 months (RMST, 7.8 vs 7.7 vs 8.1 months) or 36 months (RMST, 15.0 vs 13.9 vs 14.4 months). Compared with non-ICI therapy, ICI monotherapy showed evidence of early harm (IPW-adjusted HR within 6 months, 1.2; 95% CI, 1.1-1.2) but late benefit (adjusted HR among patients who survived 6 months, 0.8; 95% CI, 0.7-0.8). CONCLUSIONS AND RELEVANCE: In this cohort study, compared with trial-eligible patients, trial-ineligible patients with advanced cancers preferentially received first-line ICI therapy. A survival difference was not detected between ICI and non-ICI therapies among trial-ineligible patients. Positive results for ICI in phase 3 trials may not translate to this vulnerable population.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Parikh RB, Min EJ, Wileyto EP, et al. Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers. JAMA Oncol. 2021. PMID: 34734979. doi:10.1001/jamaoncol.2021.4971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。